Botulinum toxin a for nonambulatory children with cerebral palsy: A double blind randomized controlled trial

Objectives: To examine the efficacy and safety of intramuscular botulinum toxin A (BoNT-A) to reduce spasticity and improve comfort and ease of care in nonambulant children with cerebral palsy (CP). Study design: Nonambulant children with CP (n = 41; Gross Motor Function Classification System level...

Full description

Bibliographic Details
Main Authors: Copeland, L., Edwards, P., Thorley, M., Donaghey, S., Gascoigne-Pees, L., Kentish, M., Lindsley, J., McLennan, K., Sakzewski, L., Boyd, Roslyn
Format: Journal Article
Published: 2014
Online Access:http://hdl.handle.net/20.500.11937/40225
_version_ 1848755809796751360
author Copeland, L.
Edwards, P.
Thorley, M.
Donaghey, S.
Gascoigne-Pees, L.
Kentish, M.
Lindsley, J.
McLennan, K.
Sakzewski, L.
Boyd, Roslyn
author_facet Copeland, L.
Edwards, P.
Thorley, M.
Donaghey, S.
Gascoigne-Pees, L.
Kentish, M.
Lindsley, J.
McLennan, K.
Sakzewski, L.
Boyd, Roslyn
author_sort Copeland, L.
building Curtin Institutional Repository
collection Online Access
description Objectives: To examine the efficacy and safety of intramuscular botulinum toxin A (BoNT-A) to reduce spasticity and improve comfort and ease of care in nonambulant children with cerebral palsy (CP). Study design: Nonambulant children with CP (n = 41; Gross Motor Function Classification System level IV = 3, level V = 38; mean age 7.1 years, range 2.3-16 years, 66% male) were randomly allocated to receive either intramuscular BoNT-A injections (n = 23) or sham procedure (n = 18) combined with therapy. The analysis used generalized estimating equations with primary outcome the Canadian Occupational Performance Measure (COPM) at 4 weeks postintervention and retention of effects at 16 weeks. Adverse events (AE) were collected at 2, 4, and 16 weeks by a physician masked to group allocation. Results: There were significant between group differences favoring the BoNT-A-treated group on COPM performance at 4 weeks (estimated mean difference 2.2, 95% CI 0.8, 3.5; P = .002) and for COPM satisfaction (estimated mean difference 2.2, 95% CI 0.5, 3.9; P = .01). These effects were retained at 16 weeks for COPM satisfaction (estimated mean difference 1.8, 95% CI 0.1, 3.5; P = .04). There were more mild AE at 4 weeks for the BoNT-A group (P = .002), however, there were no significant between-group differences in the reporting of moderate and serious AE. Conclusions: In a double-blind randomized sham-controlled trial, intramuscular BoNT-A and therapy were effective for improving ease of care and comfort for nonambulant children with CP. There was no increase in moderate and severe AE in the children who had BoNT-A injections compared with the sham group.
first_indexed 2025-11-14T09:02:13Z
format Journal Article
id curtin-20.500.11937-40225
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:02:13Z
publishDate 2014
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-402252017-09-13T13:59:39Z Botulinum toxin a for nonambulatory children with cerebral palsy: A double blind randomized controlled trial Copeland, L. Edwards, P. Thorley, M. Donaghey, S. Gascoigne-Pees, L. Kentish, M. Lindsley, J. McLennan, K. Sakzewski, L. Boyd, Roslyn Objectives: To examine the efficacy and safety of intramuscular botulinum toxin A (BoNT-A) to reduce spasticity and improve comfort and ease of care in nonambulant children with cerebral palsy (CP). Study design: Nonambulant children with CP (n = 41; Gross Motor Function Classification System level IV = 3, level V = 38; mean age 7.1 years, range 2.3-16 years, 66% male) were randomly allocated to receive either intramuscular BoNT-A injections (n = 23) or sham procedure (n = 18) combined with therapy. The analysis used generalized estimating equations with primary outcome the Canadian Occupational Performance Measure (COPM) at 4 weeks postintervention and retention of effects at 16 weeks. Adverse events (AE) were collected at 2, 4, and 16 weeks by a physician masked to group allocation. Results: There were significant between group differences favoring the BoNT-A-treated group on COPM performance at 4 weeks (estimated mean difference 2.2, 95% CI 0.8, 3.5; P = .002) and for COPM satisfaction (estimated mean difference 2.2, 95% CI 0.5, 3.9; P = .01). These effects were retained at 16 weeks for COPM satisfaction (estimated mean difference 1.8, 95% CI 0.1, 3.5; P = .04). There were more mild AE at 4 weeks for the BoNT-A group (P = .002), however, there were no significant between-group differences in the reporting of moderate and serious AE. Conclusions: In a double-blind randomized sham-controlled trial, intramuscular BoNT-A and therapy were effective for improving ease of care and comfort for nonambulant children with CP. There was no increase in moderate and severe AE in the children who had BoNT-A injections compared with the sham group. 2014 Journal Article http://hdl.handle.net/20.500.11937/40225 10.1016/j.jpeds.2014.01.050 restricted
spellingShingle Copeland, L.
Edwards, P.
Thorley, M.
Donaghey, S.
Gascoigne-Pees, L.
Kentish, M.
Lindsley, J.
McLennan, K.
Sakzewski, L.
Boyd, Roslyn
Botulinum toxin a for nonambulatory children with cerebral palsy: A double blind randomized controlled trial
title Botulinum toxin a for nonambulatory children with cerebral palsy: A double blind randomized controlled trial
title_full Botulinum toxin a for nonambulatory children with cerebral palsy: A double blind randomized controlled trial
title_fullStr Botulinum toxin a for nonambulatory children with cerebral palsy: A double blind randomized controlled trial
title_full_unstemmed Botulinum toxin a for nonambulatory children with cerebral palsy: A double blind randomized controlled trial
title_short Botulinum toxin a for nonambulatory children with cerebral palsy: A double blind randomized controlled trial
title_sort botulinum toxin a for nonambulatory children with cerebral palsy: a double blind randomized controlled trial
url http://hdl.handle.net/20.500.11937/40225